Bengaluru, Karnataka, India, November 18, 2019
Biocon Ltd, an innovation-led global biopharmaceuticals company, is pleased to announce that its Chairperson & Managing Director Kiran Mazumdar-Shaw has been conferred with the Lifetime Achievement Award for Outstanding Achievement in Healthcare by the Indian Council of Medical Research (ICMR) for her remarkable contribution to the field of healthcare and to the society at large.
ICMR, the apex body in India for the formulation, coordination and promotion of biomedical research, recognised Ms. Mazumdar-Shaw as a thought leader for building a globally -renowned biopharmaceuticals company that is committed to innovation and is providing high-quality, affordable medicines to patients across the world. She was also recognised for her philanthropic efforts and providing better healthcare to people in India and globally through innovative, cost-effective life-saving therapies and increasing access to healthcare at the grassroots.
On receiving the Lifetime Achievement Award, Kiran Mazumdar-Shaw said: “I am honoured to receive this award from ICMR, which is one of the oldest medical research bodies in the world and has played a pivotal role in encouraging medical research to address the country’s healthcare challenges. My mission of using innovation to develop biopharmaceuticals that can benefit a billion patients and enable affordable access to medicines is quite aligned with ICMR’s purpose to create a strong ecosystem for medical research and innovation in India. I strongly believe it’s critical for us to invest in R&D to find innovative solutions to improve access and affordability of healthcare in the country to serve growing patient needs.”
Bill Gates, co-chair, Bill & Melinda Gates Foundation, presented this award to Ms. Mazumdar-Shaw in New Delhi on Nov 17, 2019 at an event to mark the celebration of the 108th Foundation Day of ICMR.
Dr Cyrus S. Poonawalla, Chairman and Managing Director, Serum Institute of India and Dr Prakash Baba Amte, Director, Lok Biradari Prakalp were also honoured with the Lifetime Achievement Award by ICMR.
Ms. Mazumdar-Shaw has been pivotal in redefining the biotechnology landscape through Biocon’s initiatives and breaking new ground through her philosophy of ensuring affordable access to life-saving biopharmaceuticals globally.
Her visionary journey has earned her several coveted titles and awards, both national and international, including India’s top civilian awards, Padma Shri and Padma Bhushan, as well as, the highest French distinction, Knight of the Legion of Honour.
Ms Mazumdar-Shaw is a well-regarded global influencer and has been named among TIME magazine’s ‘100 Most Influential People in the World’. She was given the AWSM Award for Excellence in 2017 by the Feinstein Institute for Medical Research and the Chemical Heritage Foundation conferred her with the Othmer Gold Medal in 2014. She has received the Global Economy Prize for Business in 2014 from the Kiel Institute for the World Economy, Germany, for her outstanding contribution and dedication to the biosciences and research field globally.
She has featured in the Forbes’ list of ‘World’s 100 Most Powerful Women’; Scientific American’s ‘The Worldview 100 List’ of most influential visionaries; and Fortune’s ‘Top 25 Most Powerful Women in Asia-Pacific’. She was ranked No. 1 in the Business Captains category in the Medicine Maker Power List 2018, an index of the 100 most influential people across the globe in the field of medicine.
She has been felicitated with the Lifetime Achievement Award at the FICCI Healthcare Excellence Awards 2019.
She is also a Member of the Board of Trustees of the prestigious Massachusetts Institute of Technology (MIT), U.S. and more recently she has been elected as a Member of the National Academy of Engineering, U.S.
About Biocon Ltd:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It is a leading global player for APIs including statins, immunosuppressants and specialty molecules. Biocon has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the U.S. and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Biocon is committed to pursue the path of innovation to develop products that have the potential to benefit a billion lives. Biocon Biologics is a subsidiary of Biocon Ltd. It is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in developed markets like EU, Australia, U.S. and Japan.www.biocon.com; Follow-us on Twitter: @bioconlimited